GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Readout] REDEFINE 1 and what CagriSema actually adds over sema alone — 34 comments in the full submission. View in context.
915
c/trialwatch·submitted 14 days ago by u/week_one_wanda

[Readout] REDEFINE 1 and what CagriSema actually adds over sema alone

Readoutbranch of 6 comments

Posting this as a discussion rather than a claim: REDEFINE 1 and what CagriSema actually adds over sema alone. Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight. Read a press release and the publication three months apart. The hedging in the…

Read the full submission and all 34 comments →

This branch

6 comments, started 14 days ago
u/kaia_cabrera36 points·14 days ago

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

replysharereportpermalink
u/week_four_wall10 points·14 days ago

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

replysharereportpermalink
u/anders_kuusela6 points·13 days ago

Same. A press release is a claim about a result; the publication is the result.

replysharereportpermalink
u/ines_castellanos5 points·13 days ago

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

replysharereportpermalink
u/yusuf_ramos7 points·14 days ago

Is that intention-to-treat or completers?

replysharereportpermalink
u/marit_laurent23 points·13 days ago

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →